|
|
|
Our Clients |
|
TD Group |
 |
|
|
| Pharmaceutical |
No significant impacted by the financial crisis, China's pharmaceutical market is not only a large, rising opportunity in itself – reaching an estimated $37 billion in 2008 and still growing at near 20% annually – in the near future, it will also join the world's biggest pharmaceutical markets. This makes it strategically crucial for Western pharmaceutical companies to succeed there. Due to the easy accessibility of raw material and low labor cost, increasing numbers of western companies outsource the API and intermediate R&D to China, and focus on medicine and formulate with more profit margin at home. China has become the manufacturing base for API and intermediate products in the world. API is predicted to capture 22% of the global API market by 2010, as well as the intermediate enjoy the 25% of the annual growth. In contrast, the plant extraction market in China is relatively small with the total market size counts for 500 million USD in 2008 with around 30% annual growth smoothly.
China, as of 2008, has around 6,000 domestic pharmaceutical manufacturers and around 14,000 domestic pharmaceutical distributors. The domestic pharmaceutical market has enormous potential for foreign enterprises. The lacking capability match the first class give the western pharmaceutical companies great opportunities. The cooperation area can cover such as production technology upgrade, R&D outsourcing, Contracting production, protection of intellectual property rights, drug approval procedures, corporate support for drug research and differences in the treatment in China, etc.
|
|
|
